Success Metrics

Clinical Success Rate
66.7%

Based on 4 completed trials

Completion Rate
67%(4/6)
Active Trials
2(25%)
Results Posted
50%(2 trials)
Terminated
2(25%)

Phase Distribution

Ph phase_2
1
13%
Ph phase_1
7
88%

Phase Distribution

7

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution8 total trials
Phase 1Safety & dosage
7(87.5%)
Phase 2Efficacy & side effects
1(12.5%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

66.7%

4 of 6 finished

Non-Completion Rate

33.3%

2 ended early

Currently Active

2

trials recruiting

Total Trials

8

all time

Status Distribution
Active(2)
Completed(4)
Terminated(2)

Detailed Status

Completed4
Recruiting2
Terminated2

Development Timeline

Analytics

Development Status

Total Trials
8
Active
2
Success Rate
66.7%
Most Advanced
Phase 2

Trials by Phase

Phase 17 (87.5%)
Phase 21 (12.5%)

Trials by Status

completed450%
recruiting225%
terminated225%

Recent Activity

2 active trials
Showing 5 of 8
recruitingphase_1

Safety, Tolerability and Pharmacokinetics of AZD1613 in Adults With Autosomal Dominant Polycystic Kidney Disease

NCT07228364
recruitingphase_1

A Phase 1b/2 Study of IM-101 in Adult Participants With Generalized Myasthenia Gravis and Ocular Myasthenia Gravis

NCT07250750
terminatedphase_1

A Study of Orally Administered IPG7236 in Healthy Adult Participants

NCT05288543
completedphase_1

A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4144 as Well as the Impact of AZD4144 on the Pharmacokinetics of Rosuvastatin and Furosemide in Healthy Participants

NCT06491550
completedphase_1

A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4144 Following Single and Multiple Ascending Doses Via Oral Administration to Healthy Participants

NCT06122714
View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials
NCT07228364Phase 1

Safety, Tolerability and Pharmacokinetics of AZD1613 in Adults With Autosomal Dominant Polycystic Kidney Disease

Recruiting
NCT07250750Phase 1

A Phase 1b/2 Study of IM-101 in Adult Participants With Generalized Myasthenia Gravis and Ocular Myasthenia Gravis

Recruiting
NCT05288543Phase 1

A Study of Orally Administered IPG7236 in Healthy Adult Participants

Terminated
NCT06491550Phase 1

A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4144 as Well as the Impact of AZD4144 on the Pharmacokinetics of Rosuvastatin and Furosemide in Healthy Participants

Completed
NCT06122714Phase 1

A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4144 Following Single and Multiple Ascending Doses Via Oral Administration to Healthy Participants

Completed
NCT01744704Phase 1

Study to Evaluate Safety, Tolerability and Pharmacokinetics of rhNGF Eye Drops in Healthy Volunteers

Completed
NCT01378676Phase 2

A Study to Evaluate the Effects of Multiple Doses of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)

Completed
NCT02377362Phase 1

A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GLWL-01

Terminated

All 8 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
8